A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

I8F-MC-GPGA -

The 3 main purposes of this study are to determine the safety of tirzepatide and any side effects that might be associated with it, how much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it and how tirzepatide affects the levels of blood sugar. Each participant will enroll in only one part. This study is for research purposes only, and is not intended to treat any medical condition.

Trial Summary

Age Range
21 - 70 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
Dulaglutide, Tirzepatide
Could I receive a Placebo?
Yes
Enrollment Goal
142
Trial Dates
May 11, 2016 - Jun 26, 2017
How long will I be in the trial?
Your participation in part C could last approximately 12-14 weeks and include approximately 12 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.